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Identity 
Other names: CAP1, PROSTASIN 
HGNC (Hugo): PRSS8 
Location: 16p11.2 
Local order: Centromere to telomere. 
DNA/RNA 
Description 
The human prostasin/PRSS8 gene consists of six (6) 
exons and five (5) introns. A 7-Kb (kilobase) genomic 
region containing the human prostasin/PRSS8 gene was 
fully sequenced in the original cloning report (Yu et al., 
1996), with a 1.4-kb 5'-flanking region and a 1.2-kb 3'-
flanking region. A single chromosomal location at 
16p11.2 was reported to harbor the human 
prostasin/PRSS8 gene. 
The mouse orthologue of the prostasin/prss8 gene, 
located on Chromosome 7, is highly homologous to the 
human prostasin/PRSS8 gene, with a six-exon 
organization (Verghese et al., 2004). The mouse 
prostasin/prss8 gene's 3'-untranslated region (UTR) 
overlaps with the 3'-UTR of the Myst1 histone 
acetyltransferase gene. Genetic mapping evidence 
provided support for the rat 'fuzzy' and 'hairless' 
mutations to be orthologues of the mouse 'frizzy' 
mutation (Ahearn et al., 2002). A T/A transversion 
missense mutation, changing a Val to an Asp at amino 
acid (AA) residue 170 of the mouse prostasin, was 
shown to be causative to the mutant 'frizzy' phenotype 
(Spacek et al., 2010). The 'hairless' rat has a 12-bp 
(base pair) deletion in the third exon of the prss8 gene's 
coding region, whereas the 'fuzzy' rat does not have any 
prss8 coding sequence changes. 
Transcription 
Description: The full-length human prostasin mRNA, 
as deduced from a cloned cDNA, contains a 1032-
nucleotide (nt) open-reading frame that can be 
translated into 343 AA, a 138-nt 5'-UTR, and a 572-nt 
3'-UTR (Yu et al., 1995). 
Expression: In humans, prostasin mRNA expression 
was detected by reverse-transcription coupled 
polymerase chain reaction (RT-PCR) in the total RNA 
of the prostate, liver, salivary gland, kidney, lung, 
pancreas, colon, bronchus, and renal proximal tubular 
cells (Yu et al., 1995). In the human prostate, the
prostasin mRNA was localized to the epithelial cells. 
The urinary bladder epithelial (urothelial) cells of the 
human and the mouse express the prostasin mRNA and 
the translated protein (Chen et al., 2009b; Chen et al., 
2006a). Human breast epithelial cells also express the 
prostasin mRNA and the translated protein (Chen and 
Chai, 2002; Bergum et al., 2012). Prostasin mRNA is 
expressed in the rhesus monkey endometrial glandular 
epithelium on Day 12 and Day 18 of pregnancy, and in 
the placental villi, trophoblastic column, trophoblastic 
shell, and the fetal-maternal border on Day 18 and Day
26 (Lin et al., 2006). The endometrial prostasin 
expression subsides but the placental expression 
increases further along the gestational course. 
Expression regulation: In the mouse renal cortical 
collecting duct M-1 cells prostasin mRNA expression 
can be up-regulated by aldosterone treatment, which is 
also a mechanism of increasing urinary prostasin 
excretion in rats following whole-animal infusion 
(Narikiyo et al., 2002). Aldosterone infusion was 
shown to induce prostasin mRNA expression in the left 
colon of the rat as well (Fukushima et al., 2004). 
Prostasin mRNA (and protein) expression in the M-1 
cells can be repressed by transforming growth factor  
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beta-1 (TGF-b1), via down-regulating the NF-kB 
signalling (Tuyen et al., 2005). In the mouse urinary 
bladder, prostasin mRNA expression is down-regulated 
in association with inflammation caused by 
intraperitoneal injection of bacterial 
lipopolysaccharides (LPS) (Chen et al., 2006a). 
Promoter DNA hypermethylation and histone 
deacetylation are epigenetic mechanisms that down-
regulate prostasin mRNA transcription in human breast 
and prostate cancer cell lines (Chen and Chai, 2002; 
Chen et al., 2004). Nerve growth factor (NGF) induces 
prostasin mRNA expression in human prostate cancer 
cell lines (DU-145 and PC-3) with epigenetically 
repressed prostasin expression (Chen et al., 2004). The 
sterol regulatory element-binding proteins (SREBPs) 
SREBP-1c and SREBP-2 are positive transcriptional 
regulators of prostasin expression in human epithelial 
cell lines (Chen et al., 2006b), and the binding sites of 
SREBP-2 in the human prostasin/PRSS8 gene promoter 
region have been determined (Chen et al., 2006c). The 
SNAIL family zinc-finger transcription factors SNAIL 
and SLUG are negative regulators of prostasin 
transcription in human epithelial cell lines (Chen et al., 
2006b). The SREBPs and SLUG are responsive to 
dihydrotestosterone (DHT) with up-regulation of 
expression and thus making the prostasin/PRSS8 gene 
indirectly responsive to androgen regulation (Chen et 
al., 2006b). 
Pseudogene 




The mature form of the human prostasin is 40 kDa in 
size as determined by SDS-PAGE, and has a pI in the 
range of 4.5-4.8 (Yu et al., 1994). The pro-peptide of 
the human prostasin is 311 AA in length (Yu et al.,
1995), and it is cleaved at Arg12 in the sequence of 
Gln-Ala-Arg-Ile by matriptase, hepsin, or plasmin 
(Chen et al., 2010a; Svenningsen et al., 2009) to 
produce a two-chain (12 AA and 277 AA) disulphide-
linked mature protein (Yu et al., 1995). 
Expression 
In humans the prostasin protein could be detected by 
radioimmunoassay (RIA) in tissue extracts of the 
prostate, colon, lung, kidney, pancreas, salivary gland, 
liver, and bronchi, as well as in seminal fluid and urine; 
but not in tissue extracts of the brain, muscle, testis, 
ventricle, atrium, or aorta (Yu et al., 1994). By 
immunohistochemistry (IHC), human prostasin has 
been detected in the epithelial cells of the prostate (Yu 
et al., 1994; Chen et al., 2001a), the urinary bladder 
(Chen et al., 2009b), and the breast (Bergum et al., 
2012); and the placenta trophoblasts during early 
pregnancy (Ma et al., 2009). 
Localisation 
A glycosylphosphatidylinositol (GPI) anchor tethers 
the mature prostasin protein to the plasma membrane 
(Chen et al., 2001b). The mature prostasin protein can 
be released from the membrane by 
phosphatidylinositol-specific phospholipase C (Chen et 
al., 2001b), or GPI-specific phospholipase D1 (Gpld1) 
(Verghese et al., 2006). But in the kidney shedding of 
prostasin from the cell membrane may be peptidase-
dependent (Verghese et al., 2006). In the epithelium 
proteolytic cleavage of the pro-prostasin by matriptase 
must occur at the basolateral membrane but 
transcytosis brings the GPI-anchored prostasin to its 
major cellular location, the apical membrane (Friis et 
al., 2011). 
Function 
Prostasin was first identified as a serine protease in 
human seminal fluid, purified by the use of aprotinin-
affinity chromatography (Yu et al., 1994). This native 
purified form of human prostasin displayed a trypsin-
like proteolytic activity with a pH optimum of 9.0 on 
some synthetic substrates. The serine protease catalytic 
triad of the human prostasin was deduced after the 
cloning of its cDNA, as His53/Asp102/Ser206 (Yu et 
al., 1995). A Ser206Ala mutant of the human prostasin 
was used to confirm the serine active site (Chen et al., 
2008). Using a recombinant human prostasin catalytic 
domain (i.e., lacking the GPI anchor and cellular 
context) produced in insect cells, the substrate 
specificity at the P1 position was determined to be 
either Arg or Lys (Shipway et al., 2004). The S1 
substrate subsite loop of human prostasin was found to 
bind divalent ions such as Ca++ in a crystallized form 
with protease inhibitors, suggesting that divalent 
cations can regulate the protease activity (Spraggon et 
al., 2009). 
Natural substrates: ENaC - The first candidate 
physiological substrate of prostasin was identified in a 
Xenopus kidney epithelial cell line (A6) in a functional 
cloning assay to find proteolytic activators of the 
epithelial sodium channel (ENaC), thus earning the 
nickname CAP1 (channel-activating protease 1) for 
prostasin (Vallet et al., 1997). The rat prostasin, when 
co-expressed with rat ENaC in Xenopus oocytes 
produces increased amiloride-sensitive sodium current, 
indicating ENaC activation by the co-expressed 
prostasin (Adachi et al., 2001). Activation of ENaC in 
the Xenopus oocyte requires the GPI-anchorage of the 
xCAP1 (Xenopus CAP1), indicating an extracellular 
location for the proteolytic activation of ENaC by 
xCAP1/prostasin (Vallet et al., 2002). Using a nasal 
epithelial cell line JMF/CF15 homozygous for the 
∆F508 cystic fibrosis mutation, prostasin down-
regulation by small-interfering RNA (siRNA) was 
shown to drop ENaC currents by >70% (Tong et al., 
2004).  
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The human prostasin cleaves the gamma subunit of 
ENaC at RKRK(186) (Carattino et al., 2008). In the 
mouse however, ENaC activation by mCAP1 (mouse 
CAP1) does not require its catalytic/proteolytic 
function, though the GPI anchorage is still required for 
mCAP1 in this role (Andreasen et al., 2006). 
Natural substrates: Matriptase - While an activating 
protease for pro-prostasin, matriptase has also been 
shown to be a substrate of prostasin in mouse lung 
fibroblast cells and human keratinocytes with the us of 
soluble recombinant active human prostasin (Camerer 
et al., 2010).  
This mechanism explains the activation of protease-
activated receptor 2 (PAR-2) upon addition of the 
soluble active prostasin, which accomplishes the PAR-
2 activation via activating matriptase, a direct PAR-2 
activating protease. This mechanism also helps explain 
the enhancement of matriptase cleavage of the 
extracellular domain (ECD) of the epidermal growth 
factor receptor (EGFR), which was first thought to be 
potentially cleaved by prostasin as well (Chen et al., 
2008), but later proven not to be the case (Chen et al., 
2010a).  
In human prostate epithelial cells however, prostasin 
also negatively regulate PAR-2 signalling, an action 
that requires prostasin's serine active site but not its 
GPI anchor (Chen et al., 2009a). 
Inhibitors: As a serine protease, the purified form of 
the human prostasin can be inhibited by aprotinin, 
antipain, leupeptin, and benzamidine (Yu et al., 1994).  
In the serpin-class serine protease inhibitors, protease 
nexin 1 (PN-1) is the cognate serpin for prostasin, 
forming a covalent complex with the latter to achieve 
inhibition of its serine protease activity (Chen et al., 
2004).  
In the human PN-1 reactive site, the Leu-Ile-Ala-Arg 
residues at the P4-P1 positions of this suicide inhib tor 
should represent also the optimal substrate for 
prostasin. A Kunitz-type reversible serine protease 
inhibitor, hepatocyte growth factor activator inhibitor 1 
(HAI-1) is a physiologically relevant inhibitor of 
prostasin (Fan et al., 2005; Chen et al., 2010b), whereas 
HAI-2 can inhibit the prostasin protease domain in 
vitro (Shipway et al., 2004).  
The synthetic serine protease inhibitor camostat 
mesilate and its active metabolite FOY-251 can inhibit 
prostasin serine protease activity in vitro (Maekawa et 
al., 2009), and possibly in vivo as well (Coote et al.,
2009). 
Homology 
The human prostasin was shown to share sequence  
homology at the amino acid level with acrosin, plasm  
kallikrein, and hepsin upon sequencing of its full-length 
cDNA (Yu et al., 1995).  
Prostasin also shares amino acid sequence homology  
 
 
with testisin (Hooper et al., 1999) and gamma tryptase 
(Caughey et al., 2000). 
Mutations 
Germinal 
In mice, homozygous loss of the prostasin/prss8 gene is 
embryonically lethal so conditional knockouts are 
needed for investigating prostasin/prss8 functions in 
vivo (Rubera et al., 2002).  
In humans, no Mendelian hereditary conditions on the 
basis of prostasin/PRSS8 gene mutations have been 
described to date.  
A transcribed single nucleotide polymorphism (tSNP) 
in the human prostasin/PRSS8 gene (rs12597511: C;T) 
shows genotype association with hypertension (Zhu et 
al., 2008).  
A missense SNP, E342K, of the human 
prostasin/PRSS8 gene has been reported (Li et al., 
2011). Another human prostasin/PRSS8 gene SNP, 
2827 G>A, was reported to show genotype association 
with body mass index (BMI), OGTT-2h glucose, IRT-




Prostasin expression is down-regulated in high-grade 
prostate cancers, and correspondingly in highly 
invasive human and mouse prostate cancer cell lines
(Chen et al., 2001a).  
Re-expression of prostasin in highly invasive human 
prostate cancer cell lines (DU-145 and PC-3) reduce 
their in vitro invasion.  
Down-regulated prostasin expression was associated 
with metastatic and hormone-refractory prostate 
cancers in a small study involving 54 cases (Takahashi 
et al., 2003).  
This study confirmed the inverse correlation of 
prostasin expression with histological differentiation 
but failed to find correlations with clinical stagin .  
Another small study (96 cases and 86 controls) 
suggested that RT-PCR amplification of the prostasin 
mRNA from circulating tumor cells may be applicable 
as a method for early diagnosis of prostate cancer cell 
dissemination (Laribi et al., 2001). 
Breast cancer 
Note 
A coordinated co-expression pattern in human breast 
cancers has been reported for prostasin and its 
activating enzyme/substrate matriptase (Bergum et al., 
2012). Prostasin expression is down-regulated in highly 
invasive human breast cancer cells whereas re-
expression of prostasin in these cells reduced their in 
vitro invasion (Chen and Chai, 2002). 
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Ovarian cancer 
Note 
Prostasin is detected by IHC more intensely in the 
epithelial and stromal cells of cancerous ovarian tssues 
than those of normal ovarian tissues (Mok et al., 2001). 
Serum prostasin levels may be applicable as a highly 
sensitive and specific marker for detecting ovarian 
cancer. Another study also revealed serum prostasin as 
a potentially informative marker for ovarian cancer 
(Yip et al., 2011). 
Colon cancer 
Note 
Prostasin mRNA expression was found to be correlated 
to prolonged survival after surgery in colon cancer 
patients in a small study (Cavalieri et al., 2007). In 
tissues from the same colon cancer patients, prostasin 
mRNA expression was found to be slightly increased in 
the cancerous sections whereas membrane localization 
of the prostasin protein in colon cancer tissues appe rs 
to be disturbed as well (Selzer-Plon et al., 2009). 
Other cancers 
Note 
Prostasin is among five (5) genes that can be used for 
separating the chromophobe renal cell carcinoma 
(RCC) from oncocytoma based on their differential 
mRNA expression in these two tumor types (Rohan et 
al., 2006). In the human hepatoma cell line HepG2 
prostasin mRNA expression can be reduced by poly 
unsaturated fatty acids (Fujiwara et al., 2003). 
Inflammation 
Disease 
Prostasin expression in the urinary bladder is down-
regulated by LPS-induced inflammation marked by the 
characteristic up-regulation of the inducible nitric oxide 
synthase (iNOS) expression (Chen et al., 2006a). 
Forced expression of prostasin in the bladder urothelial 
cells attenuated the iNOS induction. Silencing prostasin 
expression in the human benign prostatic hyperplasia 
cell line BPH-1 is associated with up-regulation of 
iNOS expression as well as that of interleukins 6 and 8 
(IL-6 and IL-8) (Chen et al., 2009a). In the mouse 
kidney cortical collecting duct M-1 cells, treatment 
with IL-6 was shown to increase prostasin protein 
expression (Li et al., 2010). Transgenic mice over-
expressing prostasin in the skin show skin 
inflammation and ichthyosis, phenotypes that are not 
manifested in PAR-2 null mice, indicating a PAR-2 
mediated mechanism for prostasin's role in skin 
inflammation (Frateschi et al., 2011). 
Aldosteronism and hypertension 
Note 
ENaC function related condition. 
Disease 
Consistent with aldosterone's transcriptional activtor 
role on prostasin expression, urinary excretion of 
prostasin in primary aldosteronism patients is 
significantly increased (Narikiyo et al., 2002). Rats 
receiving tail-vein injection of adenoviruses carrying a 
human prostasin transgene expressed the transgene 
ubiquitously and showed elevated plasma aldosterone 
and hypertension along with reduced urinary potassium 
excretion and increased urinary sodium and kallikrein 
excretion (Wang et al., 2003). Prostasin regulates 
aldosterone production in human adrenocortical H295R 
cells by a protease-independent but calcium- and 




Urinary prostasin level may be applicable as a marker 
for upstream ENaC activation and this marker is 
increased in primary aldosteronism patients after 
volume expansion (Olivieri et al., 2005). Another study 
also indicated a strong correlation between urinary 
prostasin levels and urinary or plasma aldosterone 
levels in hypertensive patients (Koda et al., 2009). 
Cystic fibrosis (CF) 
Note 
ENaC function related condition. 
Disease 
Prostasin was found to be a major regulator of ENaC-
mediated sodium current in a human epithelial cell line
carrying the ∆F508 CF mutation (Tong et al., 2004). In 
this context, prostasin expression in human airway 
epithelial cells can be regulated by the airway surface 
liquid (ASL) volume and CF patients express >50% 
more prostasin in their airway epithelial cells than non-




Mice born with a prostasin/prss8 knockout in the skin 
die within 60 hours, presenting a phenotype of severely 
malformed stratum corneum (SC) (Leyvraz et al., 
2005). This defect results in impaired skin barrier 
function manifested as increased skin permeability and
dehydration. At the molecular level, occludin is absent 
among the tight junction (TJ) proteins thus preventing 
the proper formation of the tight junctions and terminal 
differentiation of the epidermis. Along the same line of 
reasoning, the renal collecting duct epithelium requires 
apically expressed, GPI-anchored, and lipid-raft-
associated active prostasin serine protease for 
establishment of high transepithelial resistance (TER), 
an indicator of epithelial terminal differentiation 
(Steensgaard et al., 2010). 
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